271 related articles for article (PubMed ID: 26012728)
1. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Paller CJ; Rudek MA; Zhou XC; Wagner WD; Hudson TS; Anders N; Hammers HJ; Dowling D; King S; Antonarakis ES; Drake CG; Eisenberger MA; Denmeade SR; Rosner GL; Carducci MA
Prostate; 2015 Oct; 75(14):1518-25. PubMed ID: 26012728
[TBL] [Abstract][Full Text] [Related]
2. Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
Paller CJ; Zhou XC; Heath EI; Taplin ME; Mayer T; Stein MN; Bubley GJ; Pili R; Hudson T; Kakarla R; Abbas MM; Anders NM; Dowling D; King S; Bruns AB; Wagner WD; Drake CG; Antonarakis ES; Eisenberger MA; Denmeade SR; Rudek MA; Rosner GL; Carducci MA
Clin Cancer Res; 2018 Jan; 24(2):306-315. PubMed ID: 29113986
[No Abstract] [Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Paller CJ; Ye X; Wozniak PJ; Gillespie BK; Sieber PR; Greengold RH; Stockton BR; Hertzman BL; Efros MD; Roper RP; Liker HR; Carducci MA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):50-5. PubMed ID: 22689129
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
6. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
7. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
8. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.
Keizman D; Frenkel M; Peer A; Kushnir I; Rosenbaum E; Sarid D; Leibovitch I; Mano R; Yossepowitch O; Margel D; Wolf I; Geva R; Dresler H; Rouvinov K; Rapoport N; Eliaz I
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959847
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
11. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
Tran PT; Lowe K; Tsai HL; Song DY; Hung AY; Hearn JWD; Miller S; Proudfoot JA; Deek MP; Phillips R; Lotan T; Paller CJ; Marshall CH; Markowski M; Dipasquale S; Denmeade S; Carducci M; Eisenberger M; DeWeese TL; Orton M; Deville C; Davicioni E; Liauw SL; Heath EI; Greco S; Desai NB; Spratt DE; Feng F; Wang H; Beer TM; Antonarakis ES
J Clin Oncol; 2023 Feb; 41(6):1307-1317. PubMed ID: 36367998
[TBL] [Abstract][Full Text] [Related]
12. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.
Alumkal JJ; Slottke R; Schwartzman J; Cherala G; Munar M; Graff JN; Beer TM; Ryan CW; Koop DR; Gibbs A; Gao L; Flamiatos JF; Tucker E; Kleinschmidt R; Mori M
Invest New Drugs; 2015 Apr; 33(2):480-9. PubMed ID: 25431127
[TBL] [Abstract][Full Text] [Related]
14. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Dorff TB; Groshen S; Tsao-Wei DD; Xiong S; Gross ME; Vogelzang N; Quinn DI; Pinski JK
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):359-65. PubMed ID: 25245366
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
18. A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
van Die MD; Williams SG; Emery J; Bone KM; Taylor JM; Lusk E; Pirotta MV
Prostate; 2017 May; 77(7):765-775. PubMed ID: 28181675
[TBL] [Abstract][Full Text] [Related]
19. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
